吉非替尼治疗老年晚期非小细胞肺癌的疗效观察  

Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer

作　　者：李苏霞[1] 杨晓蕾[1] 陈素秀[1] 刘洁凡[1] 全世超[1] 

机构地区：[1]温州医学院附属第一医院

出　　处：《中国临床药理学与治疗学》2013年第12期1410-1413,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:探讨吉非替尼治疗老年晚期非小细胞肺癌的有效性和安全性。方法:对照组34例采用放疗进行治疗,观察组37例给予口服吉非替尼250mg/次,1次/日,比较两组的治疗总有效率、疾病控制率、不良反应发生率及治疗前后的血清糖蛋白型肺癌标志物(CA125)、粘蛋白型糖抗原(CA242)及癌胚抗原(CEA)水平的变化。结果:观察组治疗总有效率和疾病控制率均高于对照组(χ2=3.903,χ2=4.214,P<0.05);治疗后两组患者血清CA125、CA242及CEA水平均明显下降(P<0.05,P<0.01),观察组CA125和CEA低于对照组(P<0.05);观察组不良反应发生率低于对照组,但两组差异无统计学意义(P>0.05)。结论:吉非替尼治疗老年中晚期非小细胞肺癌患者的临床疗效确切,耐受性好,不良反应少,值得广泛推广。AIM： To investigate the effect and safety of gefitinib in elderly patients with non small cell lung cancer. METHODS： 34 elderly patients with non-small cell lung cancer treated with radiotherapy were selected as control group, and 37 patients treated with gefitinib 250mg per day were selected as observation group, then the total effective rate, disease control rates, incidence of adverse reactions and CA125,CEA, CA242 in serum of two groups were analysed and compared. RESULTS：The total effective rate and disease control rates of observation group were higher than that of control group, while the incidence of adverse reactions of two groups had no significant differences （P〉 0.05） but observation group was lower. CA125, CEA,CA242 in serum were all lower than before of two groups significant differences after the treatment （P 〈 0.05）, and observation group was lower but had no significant difference （P〉 0.05）. CONCLUSION： The effect and safety of gefitinib in elderly patients with non-small cell lung cancer was better, and incidence of adverse reaction was lower, that can obviously improve the quality of life for elderly patients.

关 键 词：吉非替尼 老年 非小细胞肺癌 CA125 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]